Please use this identifier to cite or link to this item:
|Title:||A phase II study of pazopanib in asian patients with recurrent/metastatic nasopharyngeal carcinoma|
|Authors:||Lim, W.-T. |
|Source:||Lim, W.-T., Ng, Q.-S., Ivy, P., Leong, S.-S., Singh, O., Chowbay, B., Gao, F., Thng, C.H., Goh, B.-C., Tan, D.S.-W., Koh, T.S., Toh, C.-K., Tan, E.-H. (2011-08-15). A phase II study of pazopanib in asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clinical Cancer Research 17 (16) : 5481-5489. ScholarBank@NUS Repository. https://doi.org/10.1158/1078-0432.CCR-10-3409|
|Abstract:||Purpose: Nasopharyngeal carcinoma is endemic in Asia and angiogenesis is important for Growth and progression. We hypothesized that pazopanib would have antiangiogenic activity in nasopharyngeal carcinoma. Experimental Design: A single arm monotherapy study of pazopanib in patients with WHO type II/III nasopharyngeal carcinoma who had metastatic/recurrent disease and failed at least one line of chemotherapy. A Simon's optimal 2-stage design was used. Patients with Eastern Cooperative Oncology Group (ECOG) 0-2 and adequate organ function were treated with pazopanib 800 mg daily on a 21-day cycle. The primary endpoint was clinical benefit rate (CR/PR/SD) achieved after 12 weeks of treatment. Secondary endpoints included toxicity and progression-free survival. Exploratory studies of dynamic-contrast enhanced computed tomography (DCE-CT) paired with pharmacokinetics (PK) of pazopanib was done. Results: Thirty-three patients were accrued. Patients were ECOG 0-1 with median age of 50 years (range 36-68). There were 2 (6.1%) partial responses, 16 (48.5%) stable disease, 11 (33.3%) progressive disease, 4 (12.1%) were not evaluable for response. The clinical benefit rate was 54.5% (95% CI: 38.0-70.2). Ten patients (30.3%) received more than 6 cycles (4 months) of treatment and 7 (21.2%) had PR/SD that lasted at least 6 months. One patient each died from epistaxis and myocardial infarction. Common grade 3/4 toxicities included fatigue (15.2%), hand-foot syndrome (15.2%), anorexia (9.1%), diarrhea (6.1%), and vomiting (6.1%). Serial DCE-CT scans show significant reductions in tumor blood flow, permeability surface area product, and fractional intravascular blood volume. Conclusion: Pazopanib showed encouraging activity in heavily pretreated nasopharyngeal carcinoma with an acceptable toxicity profile. ©2011 AACR.|
|Source Title:||Clinical Cancer Research|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 16, 2018
WEB OF SCIENCETM
checked on Jan 16, 2018
checked on Jan 12, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.